FDA Is Tightening the Rules on Compounded GLP-1 Drugs. What That Could Mean for Access, Safety, and Cost
FDA’s 2026 crackdown on mass-marketed compounded GLP-1s could tighten safety oversight but also shrink cheaper options for people struggling to afford approved drugs.
